← Home

SPL

Healthcare & BiotechBREAKOUT

$0.810

as of 2026-09-09

5d return

+12.5%

20d return

+16.6%

60d return

+15.7%

RSI 14

66.7

vs 52w high

+0.0%

vs 52w low

+575.0%

SMA 20

Above

SMA 50

Above

Price · Volume · Broker flow
Markers = announcements (red triangle = price-sensitive). Volume amber = ≥2× ADV spike.
Loading chart…
Closest correlates
Pearson r on log returns, window: 82d
  • LNQr=0.39, window: 82d
  • AAJr=0.30, window: 82d
  • NEUr=0.26, window: 82d
  • CUFr=0.26, window: 82d
  • DTRr=0.25, window: 82d
Announcements — last 30 days
  • 2026-09-11PSBecoming a substantial holder
  • 2026-08-26PSotherPreliminary Final Report

    SPL's 145% revenue surge driven by a one-time $8.34m Genentech upfront payment masks underlying losses of $7.47m; the company is aggressively reinvesting R&D (+34% to $11.15m) into its DEP® radiopharmaceutical platform while cash position ($11.0m) is modest against annual burn.